CompletedPhase 2NCT00227669

Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma

Studying Leiomyosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UNICANCER
Principal Investigator
Florence Duffaud, MD
CHU de la Timone
Intervention
docetaxel(drug)
Enrollment
90 enrolled
Eligibility
18-120 years · FEMALE
Timeline
20052012

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00227669 on ClinicalTrials.gov

Other trials for Leiomyosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Leiomyosarcoma

← Back to all trials